干细胞治疗迟发性性腺功能减退症的研究进展

Research progress of stem cell in the treatment of late-onset hypogonadism

迟发性性腺功能减退症(LOH)是困扰中老年男性的常见疾病。目前的睾酮替代疗法存在各种弊端。近年来,随着再生医学研究的不断发展,干细胞治疗越来越成为研究热点。本文主要介绍以诱导多能干细胞(iPSCs)、睾丸间质干细胞(SLCs)和间充质干细胞(MSCs)为来源的干细胞治疗LOH的研究进展,重点比较各方案的不同及其产生细胞的有效性和安全性。目前关于干细胞治疗仍处于早期研究阶段,治疗的安全性、免疫排斥等问题仍有待解决。相信随着研究的进展,以MSCs为代表的干细胞将在LOH治疗中发挥重要作用。

Late-onset hypogonadism(LOH)is a common disease in middle-aged and elderly men.At present,there are various disadvantages in testosterone replacement therapy.In recent years,with the continuous progress of regenerative medicine research,stem cell therapy is becoming a research hotspot.This paper mainly introduces the research progress of stem cells derived from induced pluripotent stem cells(iPSCs),stem Leydig cells(SLCs),and mesenchymal stem cells(MSCs)in the treatment of LOH,focusing on comparing among different schemes and the effectiveness and safety of the producing cells.At present,stem cell therapy is still in the early stage of research,the safety and immune rejection of the treatment remain to be solved.It is believed that with the progress of research,stem cell represented by MSCs will play an important role in the treatment of LOH in the future.